Neuland Laboratories Limited (NEULANDLAB) — Financial Results(4 announcements)

Neuland Laboratories reported Q4 FY26 revenue of ₹788.7 crores, up 134.9% YoY, and net profit of ₹212.5 crores, up 666.3% YoY, with EBITDA surging 448.6% to ₹319.4 crores and margin expanding to 40.5%. The company highlighted strong execution, upcoming peptide manufacturing investments, and R&D expansion as growth drivers. The earnings call is scheduled for 17:30 IST on May 12, 2026.

Neuland Laboratories reported a 134.9% YoY jump in quarterly revenue to Rs. 788.7 crore and a 666.3% YoY surge in net profit to Rs. 212.5 crore for Q4FY26, driven by strong growth in EBITDA and margins. The company highlighted robust business visibility and ongoing investments in peptide manufacturing and R&D to support future growth. The earnings call is scheduled for 17:30 IST on May 12, 2026.

Neuland Laboratories reported FY26 total income of ₹2053.1 crores (37.1% YoY growth), with FY26 PAT at ₹363.1 crores (40% YoY growth) and EBITDA at ₹603.4 crores (76% YoY growth). The company ended FY26 with net debt of ₹(156.8) crores, a significant improvement from ₹(228.7) crores at the end of FY25. Management highlighted strong execution in commercial molecules, progress on peptide manufacturing investments, and pipeline advancement as key growth drivers. The presentation emphasized sustainable growth through R&D expansion and strategic capex, while maintaining regulatory compliance across global markets.

Neuland Laboratories reported FY2026 revenue of ₹2,05,315.16 crores and net profit of ₹36,399.84 crores, with EPS of [amount context mismatch], reflecting strong growth from prior periods. The Board recommended a final dividend of ₹34 per share (340% payout on ₹10 face value), approved capacity expansion requiring ₹143.4 crores investment, and appointed Dr. Mauricio Futran as a Non-Executive Non-Independent Director effective May 12, 2026. The statutory auditor issued an unmodified opinion on consolidated financial results, confirming compliance with SEBI and Ind AS standards. The 42nd AGM is scheduled for August 4, 2026, with record date on July 24, 2026 for dividend eligibility.